Literature DB >> 21241987

Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.

Yoshio Matsui1, Kazuo Eguchi, Michael F O'Rourke, Joji Ishikawa, Kazuyuki Shimada, Kazuomi Kario.   

Abstract

OBJECTIVE: Excess aldosterone has a detrimental effect on large artery stiffness. We aimed to investigate the association of the change in plasma aldosterone concentration (PAC) by antihypertensive medication with the change in aortic pulse wave velocity (aPWV).
METHODS: We conducted a prospective, randomized, open-label, blinded end-point study in 207 hypertensive patients. Patients received olmesartan monotherapy for 12 weeks, followed by add-on use of hydrochlorothiazide (HCTZ; n=104) or azelnidipine (n=103) for 24 weeks after randomization. The aPWV, which was determined by measuring the carotid to femoral PWV, and laboratory data were assessed at baseline and 24 weeks later.
RESULTS: PAC in the HCTZ group increased more than that in the azelnidipine group, while aPWV and mean arterial pressure in the azelnidipine group decreased more than those in the HCTZ group. In univariable analyses, the change in PAC was significantly and positively correlated with the change in aPWV in the total population (r=0.26, P<0.001) and the HCTZ group (r=0.28, P=0.004), but not in the azelnidipine group (r=0.17, P=0.09). In multivariable analyses, a positive association of the change in PAC with the change in aPWV was observed in the total population (standardized regression coefficient β=0.18, P<0.001) and the HCTZ group (β=0.23, P=0.004), independently of the changes in covariates, but not in the azelnidipine group (β=0.13, P=0.06).
CONCLUSION: The change in PAC was significantly and positively associated with the change in aPWV in patients treated with HCTZ. These findings may partly explain why thiazide diuretics have little effect on large artery stiffness.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21241987     DOI: 10.1016/j.atherosclerosis.2010.12.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

Review 1.  Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis.

Authors:  Tracey J McGaughey; Emily A Fletcher; Sachin A Shah
Journal:  Am J Hypertens       Date:  2015-08-19       Impact factor: 2.689

2.  Reduction of plasma aldosterone and arterial stiffness in obese pre- and stage1 hypertensive subjects after aerobic exercise.

Authors:  S R Collier; K Sandberg; A M Moody; V Frechette; C D Curry; H Ji; R Gowdar; D Chaudhuri; M Meucci
Journal:  J Hum Hypertens       Date:  2014-05-01       Impact factor: 3.012

3.  Albuminuria-reducing effect of angiotensin II receptor blocker plus hydrochlorothiazide combination therapy in renal transplant recipients.

Authors:  Toshihide Naganuma; Yoshiaki Takemoto; Junji Uchida; Taiyou Ootoshi; Nobuyuki Kuwabara; Satoshi Maeda; Tatsuya Nakatani
Journal:  Exp Ther Med       Date:  2012-04-11       Impact factor: 2.447

4.  Validation of the new Complior sensor to record pressure signals non-invasively.

Authors:  Benjamin Sztrymf; Frédéric Jacobs; Denis Chemla; Christian Richard; Sandrine C Millasseau
Journal:  J Clin Monit Comput       Date:  2013-05-17       Impact factor: 2.502

Review 5.  Does Excess Tissue Sodium Storage Regulate Blood Pressure?

Authors:  Giacomo Rossitto; Christian Delles
Journal:  Curr Hypertens Rep       Date:  2022-02-22       Impact factor: 4.592

6.  Genetic variation in CYP17A1 is associated with arterial stiffness in diabetic subjects.

Authors:  Soo Jin Yang; Seung-Tae Lee; Won Jun Kim; Se Eun Park; Sung Woo Park; Jong-Won Kim; Cheol-Young Park
Journal:  Exp Diabetes Res       Date:  2012-10-23

Review 7.  Effects of Various Antihypertensive Drugs on Arterial Stiffness and Wave Reflections.

Authors:  Ming Liu; Ge-Le Li; Yan Li; Ji-Guang Wang
Journal:  Pulse (Basel)       Date:  2013-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.